Skip to main content

Table 1 Additional data that provide clinical information about the established PDOs

From: Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer

  1. Values in CA19–9 indicate U/mL. Values in DFS and OS indicate months
  2. Abbreviations: M male, F female, OS overall survival, DFS disease-free survival, mod moderately differentiated adenocarcinoma, poor poorly differentiated adenocarcinoma, AJCC American joint committee on Cancer, UICC International Union against Cancer, CA19–9 carbohydrate antigen 19–9, GEM gemcitabine, IMRT intensity-modulated radiotherapy, S-1 Tegafur, Gimeracil, Oteracil potassium, IPMN Intraductal papillary mucinous neoplasm, GnP gemcitabine and nab-paclitaxel, NA data not available, chemo chemotherapy, iv intravenous injection, CPT11 irinotecan
  3. *M1 by peritoneal dissemination, **M1 by metastasis to para-aortic lymph node
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us